Global Non-Infectious Macular Edema Treatment Strategic Business Report 2022: 46 Companies Featured Including AbbVie, Alimera Sciences, Allergan and Amgen - ResearchAndMarkets.com

2022-12-12

DUBLIN--(BUSINESS WIRE)--The "Non-Infectious Macular Edema Treatment: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

'Non-Infectious Macular Edema Treatment: Global Strategic Business Report'

The global market for Non-Infectious Macular Edema Treatment estimated at US$12.7 Billion in the year 2020, is projected to reach a revised size of US$18.6 Billion by 2027, growing at a CAGR of 5.6% over the analysis period 2020-2027.

Anti-VEGF, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$12.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroids segment is readjusted to a revised 6.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.8 Billion, While China is Forecast to Grow at 5.2% CAGR

The Non-Infectious Macular Edema Treatment market in the U.S. is estimated at US$3.8 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 4.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Immunosuppressants Segment to Record 6.2% CAGR

In the global Immunosuppressants segment, USA, Canada, Japan, China and Europe will drive the 6.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$979.8 Million in the year 2020 will reach a projected size of US$1.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 46 Featured) -

AbbVie, Inc.

Alimera Sciences, Inc.

Allergan PLC

Amgen, Inc.

Bausch Health Companies, Inc.

Bayer AG

Clearside Biomedical, Inc.

F. Hoffmann-La Roche AG

Novartis International AG

Pfizer, Inc.

What's New for 2022?